EW

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Edwards Lifesciences Corp

Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
CEO
Michael Mussallem
Employees
14900
Headquarters

1 Edwards Way
Irvine, California 92614-5688
Phone: 19492502500
www.edwards.com

News

Edwards Lifesciences Corporatio – Consensus Indicates Potential 11.4% Upside
Aug 17, 2022 11:08am

Edwards Lifesciences Corporatio found using ticker (EW) now have 19 analysts in total covering the stock. The consensus rating is ''Buy''. The target price ranges between 135 and 97 with the average target price sitting at 116.68. Given that the stocks previous close was at 104.74 this would imply there is a potential upside of 11.4%. The 50 day moving average now sits at 98.24 and the 200 moving average now moves to 109.17. The company has a market cap of $64,933m. Visit the company website at: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $72,335m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.


Source:DirectorsTalk
Edwards Lifesciences: Stretched Valuation And Bearish Resistance In Play (NYSE:EW)
Aug 15, 2022 19:19pm

Momentum''s shift into the Health Care sector proved ill-timed last May. Edwards Lifesciences has outperformed lately, but shares are not cheap, and the technical picture is somewhat bearish.


Source:Seeking Alpha
Edwards Lifesciences Corporatio – Consensus Indicates Potential 10.6% Upside
Aug 10, 2022 12:07pm

Edwards Lifesciences Corporatio found using ticker (EW) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 135 and 97 with a mean TP of 116.68. Given that the stocks previous close was at 105.46 this would indicate that there is a potential upside of 10.6%. There is a 50 day moving average of 97.79 and the 200 day moving average is 109.49. The company has a market capitalisation of $62,887m. You can visit the company''s website by visiting: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $69,578m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.


Source:DirectorsTalk
Edwards Lifesciences EW Technical Pivots with Risk Controls
Aug 07, 2022 14:15pm

Technical analysis for Edwards Lifesciences EW including support levels resistance levels and stop losses for EW


Source:Stock Traders Daily
RXNT Named to the Top 100 Companies in Healthcare Technology
Aug 05, 2022 18:30pm


Source:Kwhen Finance
Edwards Lifesciences Corporatio – Consensus Indicates Potential 17.4% Upside
Aug 03, 2022 12:00pm

Edwards Lifesciences Corporatio with ticker code (EW) have now 19 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 135 and 98 with a mean TP of 116.79. Given that the stocks previous close was at 99.45 this indicates there is a potential upside of 17.4%. The day 50 moving average is 96.97 and the 200 moving average now moves to 109.73. The company has a market capitalisation of $63,371m. Visit the company website at: https://www.edwards.com [stock_market_widget type="chart" template="basic" color="green" assets="EW" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $74,420m based on the market concensus. Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.


Source:DirectorsTalk
Monday’s Top Analyst Upgrades and Downgrades: Carlyle Group, Deckers Outdoor, Edwards Lifesciences, Meta Platforms, Qualcomm, Spirit Airlines, Wingstop and More – 24/7 Wall St.
Aug 01, 2022 12:52pm

The futures are lower on Monday as we start August after an outstanding July that saw the biggest gains for the stock market in months. All of the major indices closed higher on Friday as once again the Nasdaq led the way rising close to 2%. Strong results and positive guidance from mega-cap technology giants […]


Source:24/7 Wall street
Notable Friday Option Activity: EW, PYPL, ETSY
Jul 29, 2022 21:56pm

Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Edwards Lifesciences Corp (Symbol: EW), where a total volume of 12,441 contracts has been traded thus far today, a contract volume which is representative of app


Source:Nasdaq
Here''s How Much $100 Invested In Edwards Lifesciences 10 Years Ago Would Be Worth Today
Jul 29, 2022 18:38pm

Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 10 years by 8.15% on an annualized basis producing an average annual return of 19.8%. Currently, Edwards Lifesciences has a market capitalization of $62.66 billion. Buying $100 In EW: If … Full story available on Benzinga.com


Source:Benzinga
Edwards Lifesciences Down on Earnings Miss as Hospital Staffing ''Remains Uncertain''
Jul 29, 2022 17:44pm

https://www.investing.com/news/stock-market-news/edwards-lifesciences-down-on-earnings-miss-as-hospital-staffing-remains-uncertain-432SI-2858454


Source:Investing.com
Edwards Lifesciences (EW) Q2 2022 Earnings Call Transcript
Jul 29, 2022 10:30am

EW earnings call for the period ending June 30, 2022.


Source:The Motley Fool
Canaccord Genuity Downgrades Edwards Lifesciences to Hold
Jul 29, 2022 10:01am

https://www.investing.com/news/pro/canaccord-genuity-downgrades-edwards-lifesciences-to-hold-432SI-2857777


Source:Investing.com
Edwards Lifesciences PT Raised to $118 at Citi
Jul 29, 2022 08:03am

https://www.investing.com/news/pro/edwards-lifesciences-pt-raised-to-118-at-citi-432SI-2857658


Source:Investing.com
Edwards Lifesciences Corporation (EW) CEO Mike Mussallem on Q2 2022 Results - Earnings Call Transcript
Jul 29, 2022 00:00am

Edwards Lifesciences Corporation (NYSE:NYSE:EW) Q2 2022 Earnings Conference Call July 28, 2022, 05:00 PM ET Company Participants Mark Wilterding - VP, IR and Treasurer Mike Mussallem -…


Source:Seeking Alpha
Edwards Lifesciences Shares Slide As Q2 Results Miss Expectations, Lowers FY22 Sales Outlook
Jul 28, 2022 20:54pm

Edwards Lifesciences Corp (NYSE: EW ) reported second-quarter sales of $1.37 billion , flat compared to 2Q21, missing the consensus of $1.4 billion. Adjusted EPS was $0.63, which missed the consensus of $0.64. The adjusted gross profit margin was 80.5% for the quarter, compared to 75.9% in 2Q21. Transcatheter aortic valve replacement sales … Full story available on Benzinga.com


Source:Benzinga
Edwards Lifesciences Q2 2022 Earnings Preview
Jul 27, 2022 21:35pm

Edwards Lifesciences (EW) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close.The consensus EPS Estimate is $0.64 (flat Y/Y) and the consensus…


Source:Seeking Alpha
Edwards Lifesciences Corporation (NYSE: EW) Down -6.21% This Year: What Is Going To Happen Next
Jul 27, 2022 17:00pm

Edwards Lifesciences Corporation (NYSE:EW) price is hovering higher on Wednesday, July 27, jumping 2.21% above its previous close. A look at today’s price movement shows that the recent level at last check reads $102.13, with intraday deals fluctuating between $101.29 and $102.50. The company’s 5Y monthly beta was ticking 1.14 while its P/E ratio in … Edwards Lifesciences Corporation (NYSE: EW) Down -6.21% This Year: What Is Going To Happen Next Read More »


Source:Stocks Register
Looking Into Edwards Lifesciences''s Recent Short Interest
Jul 18, 2022 16:02pm

Edwards Lifesciences''s (NYSE: EW ) short percent of float has fallen 64.56% since its last report. The company recently reported that it has 6.21 million shares sold short , which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.2 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com


Source:Benzinga
Here''s How Much You Would Have Made Owning Edwards Lifesciences Stock In The Last 15 Years
Jul 13, 2022 17:15pm

Edwards Lifesciences (NYSE: EW ) has outperformed the market over the past 15 years by 17.08% on an annualized basis producing an average annual return of 23.24%. Currently, Edwards Lifesciences has a market capitalization of $60.18 billion. Buying $1000 In EW: If … Full story available on Benzinga.com


Source:Benzinga
TherapeuticsMD Announces Expiration of Tender Offer
Jul 13, 2022 10:50am

TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women’s healthcare company, announced today that Athene Merger, Inc., an affiliate of EW Healthcare Partners (“EW”), did not acquire the required majority of shares of TXMD through the previously announced tender offer by the extended offer deadline of one minute after 11:59 PM Eastern Time on July


Source:Wallstreet:Online
Are Value Hunters Buying Edwards Lifesciences Corporation (NYSE: EW) Stock?
Jul 12, 2022 19:00pm

The trading price of Edwards Lifesciences Corporation (NYSE:EW) floating higher at last check on Tuesday, July 12, closing at $97.09, 0.22% higher than its previous close. >> 5 Best Growth Stocks for 2022 << >> 5 Best Growth Stocks for 2022 << Traders who pay close attention to intraday price movement should know that it … Are Value Hunters Buying Edwards Lifesciences Corporation (NYSE: EW) Stock? Read More »


Source:Stocks Register
EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer
Jul 06, 2022 10:09am

TherapeuticsMD has previously stated that absent the successful closing of this transaction, the Company would likely be required to file for protection under Chapter 11. BOCA RATON, Fla. , July 6 , 2022 /PRNewswire/ -- EW Healthcare Partners ("EW"), has announced that Athene Merger, Inc. ("Offeror"), an affiliate of EW, has extended the expiration date of its tender offer (the "Offer") to purchase all issued and outstanding shares of TherapeuticsMD, Inc. (NASDAQ: TXMD ), ("TXMD" or the "Company") at a price of $10.00 per share until one minute after 11:59 PM , New York City time, on July 12, 2022 , unless further extended in accordance with the terms of the Merger Agreement and the applicable rules and regulations of the SEC. As of 6:30 PM , New York City time, on July 5, 2022 , 2,584,893 shares of TXMD, representing approximately 29.2% of the issued and outstanding shares, were tendered pursuant to the Offer. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to this extension.


Source:Benzinga
Cameron Diaz is back to show it’s not all over for actresses after 40 | Rebecca Nicholson
Jul 02, 2022 16:00pm

The one-time queen of romcoms has come out of retirement to join the growing ranks of women stars of action movies Cameron Diaz retired from acting after her last film – a remake of Annie in which she played Miss Hannigan – was released in 2014. She casually confirmed that she was no longer acting in an interview with EW in 2018, telling her co-stars of the early noughties romcom The Sweetest Thing that she was “actually retired”. Two years later, she expanded on her decision to step away from Hollywood, telling Gwyneth Paltrow that she had grown tired of being “infantilised” by her industry and realised she had to learn how to become self-sufficient. The move brought her, she said at the time, “a peace in my soul”. Obviously, Diaz has since learned how to boil the kettle and make herself a cuppa, because she is coming out of retirement after eight years. Jamie Foxx broke the news on Twitter, announcing that he and Diaz would be starring in a new film for Netflix called, appropriately, Back in Action .


Source:The Guardian
Analyzing Edwards Lifesciences''s Short Interest
Jun 30, 2022 17:05pm

Edwards Lifesciences''s (NYSE: EW ) short percent of float has risen 166.36% since its last report. The company recently reported that it has 5.87 million shares sold short , which is 2.85% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.0 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com


Source:Benzinga
How can you protect wearable sensor IP?
Jun 30, 2022 00:00am

At the Wear 2022 Conference, Jerrah Edwards, the Acting Assistant Regional Director of the Western Regional United States Patent and Trademark Office (USPTO) presented “Intellectual property (IP) Strategies Wearable Technology Startups Should Consider.” While focusing specifically on wearables, the strategies apply to any technology or sensing area. Her discussion Included an overview of intellectual property […]


Source:WTWH
Investors are Watching These 5 Biotech Stocks
Jun 27, 2022 15:01pm

Edwards Lifesciences Corporation (NYSE:EW) provides healthcare equipment for critical care.


Source:Insider Monkey